Gastroenterology Research and Practice / 2017 / Article / Tab 4

Research Article

Factors Related to Significant Improvement of Estimated Glomerular Filtration Rates in Chronic Hepatitis B Patients Receiving Telbivudine Therapy

Table 4

Factors related to the improvement of eGFR (CKD-EPI) (increase in eGFR > 10%) according to univariate and multivariate logistic regressions.

Risk factorUnivariate valueMultivariate value
HR (95% CI)HR (95%CI)

Age: ≥50 years2.221 (1.070–4.611)0.0321.315 (0.576–3.001)0.516
Sex: male0.987 (0.423–2.305)0.976
HBeAg: positive0.663 (0.308–1.427)0.293
Cirrhosis0.785 (0.333–1.849)0.580
Decompensation0.929 (0.342–2.520)0.885
Hepatocellular carcinoma1.101 (0.338–3.583)0.873
HBV genotype: type B0.518 (0.222–1.209)0.128
Baseline ALT > 200 U/L1.031 (0.494–2.154)0.935
Baseline HBV DNA: <7 log IU/mL1.222 (0.564–2.650)0.611
Baseline eGFR < 60 mL/min/1.73 m27.117 (1.849–27.399)0.0044.560 (1.046–19.875)0.043
Diabetes mellitus5.958 (1.776–19.993)0.0044.194 (1.165–15.098)0.028
Hypertension0.931 (0.436–3.874)0.864
Add-on adefovir therapy0.477 (0.186–1.222)0.123
Complete virological response at month 61.670 (0.778–3.585)0.189
Contrast medium exposure1.101 (0.338–3.583)0.873

ALT: alanine transaminase; HBeAg: hepatitis B e-antigen; HR: hazard ratio.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.